To Bolster Pipeline, Glaxo Exec Scouts Prospects

For the 8,000 drug-company executives, investors and others attending the annual J.P. Morgan health-care conference in San Francisco, the last few days have been a marathon of morning-to-night meetings.

But the industry executives do it because of the potential payoff: new deals with other companies to build up drug-research pipelines …